Therapeutic monitoring of the new antiepileptic drugs

European Journal of Clinical Pharmacology

Volumn 55, Issue 10, 2000, Pages 697-705

  Tomson, T ^a   Johannessen, S I ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b National Center for Epilepsy   (Norway)

Author keywords

Antiepileptic drugs; Therapeutic drug monitoring

Indexed keywords

ANTICONVULSIVE AGENT; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENYTOIN; TIAGABINE; TOPIRAMATE; VIGABATRIN; ZONISAMIDE;

ANTICONVULSANT THERAPY; CONCENTRATION RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; EPILEPSY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0033963848     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050001     Document Type: Review

References (94)

1. 1. Buchthal F, Svensmark O (1960) Aspects of pharmacology of phenytoin (Dilantin) and phenobarbital relevant to their dosage in the treatment of epilepsy. Epilepsia 1: 373-384
2. 2. Kutt H, Penry JK (1974) Usefulness of blood levels of antiepileptic drugs. Arch Neurol 31: 283-288
3. 3. Chadwick D (1987) Overuse of monitoring of blood concentrations of antiepileptic drugs. BMJ 294: 723-724
4. 4. Schoenenberger RA, Tanasijevic MJ, Jha A, Bates DW (1995) Appropriateness of antiepileptic drug level monitoring. JAMA 274: 1622-1626
5. 5. Commission on Antiepileptic Drugs (1993) Guidelines for therapeutic monitoring on antiepileptic drugs. Epilepsia 34: 585-587
6. 6. Aronson JK, Hardman M, Reynolds DJM (1992) ABC of monitoring drug therapy, phenytoin. BMJ 305: 1215-1218
7. 7. Johannessen SI (1997) Plasma drug concentration monitoring of anticonvulsants. Practical guidelines. CNS Drugs 7: 349-365
8. 8. Eadie MJ (1998) Therapeutic drug monitoring - antiepileptic drugs. Br J Clin Pharmacol 46: 185-193
9. 9. Brodie MJ (1998) Routine measurement of new antiepileptic drug concentrations: a critique and a prediction. In: French J, Leppik I, Dichter MA (eds) Antiepileptic drug development. (Advances in neurology, vol 76). Lippincott-Raven Publishers, Philadelphia, p 223
10. 10. Patsalos PN (1999) New antiepileptic drugs. Ann Clin Biochem 36: 10-19
11. 11. Gross AS (1998) Best practice in therapeutic drug monitoring. Br J Clin Pharmacol 46: 95-99
12. 12. Lund L (1974) Anticonvulsant effect of diphenylhydantoin relative to plasma levels. Arch Neurol 31: 289-294
13. 13. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perruca E (1999) Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT VI). Epilepsy Res 34: 1-41
14. 14. Petroff OAC, Rothman DL, Behar KL, Lamoureux D, Mattson RH (1996) The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy. Ann Neurol 39: 95-99
15. 15. Goa KL, Sorkin EM (1993) Gabapentin. A review of its pharmacological properties and clinical potential in epilepsy. Drugs 46: 409-427
16. 16. Vollmer K, Anhut H, Thomann P, Wagner F, Jänchen D (1989) Pharmacokinetic model and absolute bioavailability of the new anticonvulsant gabapentin. In: Manelis J, Bental E, Loeber JN, Dreifuss FE (eds) Advances in epileptology. XVIIth Epilepsy International Symposium. Raven, New York, pp 209-211
17. 17. Ben-Menachem E, Söderfelt B, Hamberger T, Hedner T, Persson LI (1995) Seizure frequency and CSF parameters, a double-blind, placebo-controlled trial of gabapentin patients with intractable complex partial seizures. Epilepsy Res 21: 231-226
18. 18. Wilson EA, Sills GJ, Forrest G, Brodie MJ (1998) High dose gabapentin in refractory partial epilepsy: clinical observations in 50 patients. Epilepsy Res 29: 161-166
19. 19. Sivenius J, Kälviäinen R, Ylinen A, Riekkinen P (1991) Double blind study of gabapentin in the treatment of partial seizures. Epilepsia 32: 539-542
20. 20. Julian G, Jambor LG, Grove TH (1995) The analysis of gabapentin by HPLC. Clin Chem 41: S117
21. 21. Lensmeyer GL, Kempf T, Gidal BE, Wiebe DA (1995) Optimized method for determination of gabapentin in serum by high-performance liquid chromatography. Ther Drug Monit 17: 251-258
22. 22. Forest G, Sills GJ, Leach JP, Brodie MJ (1996) Determination of gabapentin in plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 681: 421-425
23. 23. Jürgens U, May TH, Rambeck B (1996) Simultaneous HPLC determination of vigabatrin and gabapentin in serum with automated pre-injection derivatization. J Liquid Chromatogr Related Technol 19: 1459-1471
24. 24. Ratnaraj N, Patsalos PN (1998) A micromethod for the simultaneous determination of vigabatrin and gabapentin in serum by high performance liquid chromatography. Ther Drug Monit 19: 252-260
25. 25. Cohen AF, Land GS, Breimer DD, Yuen W, Winton C, Peck AW (1987) Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin Pharmacol Ther 42: 535-541
26. 26. Eriksson A-S, Hoppu L, Nergårdh A, Boréus L (1996) Pharmacokinetic interactions between lamotrigine and other antiepileptic drugs in children with intractable epilepsy. Epilepsia 37: 769-773
27. 27. May TW, Rambeck B, Jürgens U (1996) Serum concentrations of lamotrigine in epileptic patients: the influence of dose and comedication. Ther Drug Monit 18: 523-531
28. 28. Jawad S, Yuen AWC, Peck AW, Hamilton MJ, Oxley JR, Richens A (1987) Lamotrigine: single-dose pharmacokinetics and initial one-week experience in refractory epilepsy. Epilepsy Res 1: 194-210
29. 29. Yau MK, Wargin WA, Wolf KB, Lai AA, Dren AT, Harris SI, Morse IS (1992) Effect of valproate on the pharmacokinetics of lamotrigine (Lamictal) at steady state. Epilepsia 33 [Suppl 3]: 82
30. 30. Bartoli A, Guerrini R, Belmonte A, Alessandri MG, Gatti G, Perruca E (1997) The influence of dosage, age and comedication on steady-state plasma lamotrigine concentrations in epileptic children: a prospective study with preliminary assessment of correlations with clinical response. Ther Drug Monit 19: 252-260
31. 31. Posner J, Holdich T, Crome P (1991) Comparison of lamotrigine pharmacokinetics in young and elderly healthy volunteers. J Pharm Med 1: 121-128
32. 32. Tomson T, Öhman I, Vitols S (1997) Lamotrigine in pregnancy and lactation: a case report. Epilepsia 38: 1039-1040
33. 33. George S, Wood AJ, Braithwaite RA (1995) Routine therapeutic monitoring of lamotrigine in epileptic patients using a simple and rapid high performance liquid Chromatographic technique. Ann Clin Biochem 32: 584-588
34. 34. Brodie MJ, Richens A, Yuen AWC (1995) Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 345: 476-479
35. 35. Morris RG, Black AB, Harris AL, Batty AB, Sallustio BC (1998) Lamotrigine and therapeutic drug monitoring: retrospective survey following the introduction of a routine service. Br J Clin Pharmacol 46: 547-551
36. 36. Schapel G, Black A, Lam E, Robinson M, Dollman W (1996) Combination vigabatrin and lamotrigine therapy for intractable epilepsy. Seizure 5: 51-56
37. 37. Kilpatric ES, Forrest G, Brodie M (1996) Concentration-effect and concentration-toxicity relations with lamotrigine: a prospective study. Epilepsia 37: 534-538
38. 38. Eriksson A-S, Nergårdh A, Hoppu K (1998) The efficacy of lamotrigine in children and adolescents with refractory generalized epilepsy: a randomized, double-blind, cross-over study. Epilepsia 39: 495-501
39. 39. Gidal BE, Welty TE (1997) Letters to the editor. Epilepsia 38: 260
40. 40. Fraser AD, MacNeil W, Isner AF, Camield PR (1995) Lamotrigine analysis in serum by high-performance liquid chromatography. Ther Drug Monit 17: 174-178
41. 41. Forssblad E, Ericksson AS, Beck O (1996) Liquid Chromatographic determination of lamotrigine in pediatric samples. J Pharm Biomed Anal 14: 755-758
42. 42. Ramachandran S, Underhill S, Jones SR (1994) Measurement of lamotrigine under conditions measuring phenobarbitone, phenytoin and carbamazepine using reversed-phase high-performance liquid chromatography at dual wavelengths. Ther Drug Monit 16: 75-82
43. 43. Lensmeyer GL, Gidal BE, Wiebe DA (1997) Optimized high-performance liquid chromatography determination of lamotrigine in serum with concomitant determination of phenytoin, carbamazepine, and carbamazepine epoxide. Ther Drug Monit 19: 292-300
44. 44. Schmutz M, Brugger F, Gentsch C, McLean MJ, Olpe HR (1994) Oxcarbazepine: preclinical anticonvulsant profile and putative mechanisms of action. Epilepsia 35 [Suppl 5]: S47-S50
45. 45. Lloyd P, Flesch G, Dieterle W (1994) Clinical pharmacology and pharmacokinetics of oxcarbazepine. Epilepsia 35 [Suppl 3]: S10-S13
46. 46. Baruzzi A, Albani F, Riva R (1994) Oxcarbazepine: pharmacokinetic interactions and their clinical relevance. Epilepsia 35 [Suppl 3]: S14-S19
47. 47. Friis ML, Kristensen O, Boas J, Dalby M, Deth SH, Gram L, Mikkelsen M, Pedersen B, Sabers A, Worm-Petersen J, Andersen D, Jensen PK (1993) Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment. Acta Neurol Scand 87: 224-227
48. 48. Van Parys JAP, Meinardi H (1994) Survey of 260 patients treated with oxcarbazepine (Trileptal) on a named-patient basis. Epilepsy Res 19: 79-85
49. 49. Borusiak P, Korn-Merker E, Holert N, Boenigk HE (1998) Oxcarbazepine in treatment of childhood epilepsy: a survey of 46 children and adolescents. J Epilepsy 11: 355-360
50. 50. Nedelman JR, Gasparini M, Hossain M, Sallas W, Chang SW, Flesh G, D'Souza J (1999) Oxcarbazepine: analysis of concentration-efficacy/safety relationships. Neurology 52 [Suppl 2]: A524-A525
51. 51. Kristensen O, Klitgaard A, Jönsson B, Sindrup S (1983) Pharmacokinetics of 10-OH-carbazepine, the main metabolite of the antiepileptic oxcarbazepine, from serum and saliva concentrations. Acta Neurol Scand 68: 145-150
52. 52. Kumps A (1984) Simultaneous HPLC determination of oxcarbazepine, carbamazepine and their metabolites in serum. J Liquid Chromatogr 7: 1235-1241
53. 53. Wad N (1984) Simultaneous determination of eleven antiepileptic compounds in serum by high-performance liquid chromatography. J Chromatogr 305: 127-133
54. 54. Von Unruh GE, Paar J (1985) Gas Chromatographic assay for oxcarbazepine and its main metabolites in plasma. J Chromatogr 345: 67-76
55. 55. Elyas AA, Goldberg VD, Patsalos PN (1990) Simple and rapid microanalytical high-performance liquid Chromatographic technique for the assay of oxcarbazepine and its primary active metabolite 10-hydroxycarbazepine. J Chromatogr 528: 473-479
56. 56. Van Heiningen PNM, Eve MD, Oosterhuis B, Jonkman JH, de Bruin H, Hulsman JA, Richens A, Jensen PK (1991) The influence of age on the pharmacokinetics of the antiepileptic agent oxcarbazepine. Clin Pharmacol Ther 54: 410-419
57. 57. Adkins JC, Noble S (1998) Tiagabine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy. Drugs 55: 437-460
58. 58. Brodie MJ (1995) Pharmacology-tiagabine in profile. In: Tiagabine: the art of epilepsy care. Proceedings of a satellite symposium to the 21st International Epilepsy Congress. 2 Sep 1995, Sydney: Novo nordisk, pp 8-12
59. 59. So EL, Wolff D, Graves NM, Leppik IE, Cascino GD, Pixton GC, Gustavson LE (1995) Pharmacokinetics of tiagabine as add-on therapy in patients taking enzyme-inducing antiepileptic drugs. Epilepsy Res 22: 221-226
60. 60. Samara E, Gustavson L, El Shourbagy T, Granneman R, Sommerville K (1997) Population analysis of the pharmacokinetics of tiagabine (Gabitril). Epilepsia 38 [Suppl 3]: 145
61. 61. Rowan AJ, Gustavson L, Shu V, Sommerville KW (1997) Dose concentration relationship in a multicentre tiagabine (Gabitril) trial. Epilepsia 38 [Suppl 3]: 40
62. 62. Gustavson LE, Chu SY (1992) High-performance liquid Chromatographic procedure for the determination of tiagabine concentrations in human plasma using electrochemical detection. J Chromatogr 574: 313-318
63. 63. Rustum AM, Menon G, Patel S (1998) Separation of the S(+) and R(-)-enantiomers of tiagabine, HCl and its two chiral precursors by chiral chromatography: application to chiral inversion studies. J Pharm Biomed Anal 17: 1439-1447
64. 64. Shank RP, Vaught JL, Raffa R, Maryanoff BE (1991) Investigation of the mechanism of topiramatés anticonvulsant activity. Epilepsia 32 [Suppl 3]: 7-8
65. 65. Easterling DE, Zakszewski T, Moyer MD, Margul BL, Marriott TB, Nayak RK (1988) Plasma pharmacokinetics of topiramate, a new anticonvulsant in humans. Epilepsia 29: 662
66. 66. Johannessen SI (1997) Pharmacokinetics and interactions of topiramate. Epilepsia 38 [Suppl 1]: S18-S23
67. 67. Ramsay RE, Slater JD (1993) Antiepileptic drugs in clinical development. In: French JA, Dichter MA, Leppik IE (eds) New antiepileptic drug development, preclinical and clinical aspects. Epilepsy Res [Suppl 10], Elsevier, Amsterdam, pp 45-67
68. 68. Sachdeo RC, Sachdeo SK, Walker SA, Kramer LD, Nayak RK, Doose DR (1996) Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 37: 774-780
69. 69. Rosenfeld WE, Liao S, Kramer LD, Anderson G, Palmer M, Levy RH, Nayak RK (1997) Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 38: 324-333
70. 70. Reife RA (1996) Topiramate. In: Shorvon S, Dreifuss F, Fish D, Thomas D (eds) The treatment of epilepsy. Blackwell Science, Oxford, pp 471-481
71. 71. Reife RA, Pledger G, Doose D, Lim P, Ward C (1995) Topiramate PK/PD analysis. Epilepsia 36 [Suppl 3]: S152
72. 72. Perruca E, Bialer M (1996) The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. Clin Pharmacokinet 31: 29-46
73. 73. Penovich PE, Schroeder-Gustafson M, Gates JR, Moriarty GL (1997) Clinical experience with topiramate: correlation of serum levels with efficacy and adverse events. Epilepsia 38 [Suppl 8]: 181
74. 74. Holland ML, Uetz JA, Kung NG (1988) Automated capillary gas Chromatographic assay using flame ionization detection for the determination of topiramate in plasma. J Chromatogr B Biomed Sci Appl 433: 276-281
75. 75. Oxis International Inc (1997) Innofluor topiramate assay system reagent pack insert data sheet (number 7562.0597). Oxis International Inc, Portland, Oregon
76. 76. Richens A (1989) Potential antiepileptic drugs: vigabatrin. In: Levy R, Mattson R, Meldrum B, Penry JK, Dreifuss FE (eds) Antiepileptic drugs, 3rd edn. Raven Press, New York, pp 937-946
77. 77. Schechter PJ (1989) Clinical pharmacology of vigabatrin. Br J Clin Pharmacol 27 [Suppl 1]: 19S-22S
78. 78. Frisk-Holmberg M, Kerth P, Meyer PH (1989) Effect of food on the absorption of vigabatrin. Br J Clin Pharmacol 27: 23S-25S
79. 79. Rimmer EM, Richens A (1989) Interaction between vigabatrin and phenytoin. Br J Clin Pharmacol 27: 27S-33S
80. 80. Arteaga R, Herranz JL, Valdizán EM, Armijo JA (1992) γ-Vinyl GABA (Vigabatrin): relationship between dosage, plasma concentrations, platelet GABA-transaminase inhibition, and seizures reduction in epileptic children. Epilepsia 33: 923-931
81. 81. Löscher W, Fassbender CP, Gram L, Gramer M, Hörstermann D, Zahner B, Stefan H (1993) Determination of GABA and vigabatrin in human plasma by a rapid and simple HPLC method: correlation between clinical repsonse to vigabatrin and increase in plasma GABA. Epilepsy Res 14: 245-255
82. 82. Erdal J, Gram L, Alving J, Löscher W (1999) Changes in plasma GABA concentration during Vigabatrin treatment of epilepsy: a prospective study. Epilepsy Res 34: 145-150
83. 83. Smithers JA, Lang JF, Okerholm RA (1985) Quantitative analysis of vigabatrin in plasma and urine by reversed-phase high-performance liquid chromatography. J Chromatogr 341: 232-238
84. 84. Tsanaclis LM, Wick J, William J, Richens (1991) Determination of vigabatrin in plasma by reversed-phase high-performance liquid chromatography. Ther Drug Monit 13: 251-253
85. 85. Ito T, Yamaguchi T, Miyazaki H, Sekine Y, Shimizu M, Ishida S, Yagi K, Kakegawa N, Seino M, Wada T (1982) Pharmacokinetic studies of AD-810, a new antiepileptic compound: phase I trials. Arzneimittelforschung 32: 1581-1586
86. 86. Matsumoto K, Miyazaki H, Fujii T, Kagemoto A, Maeda T, Hashimoto M (1983) Absorption, distribution and excretion of 3-(sulfamoyl(14C)methyl)-1,2-benzioxazole (AD-810) in rats, dogs and monkeys and of AD-810 in man. Arzneimittelforschung 233: 961-968
87. 87. Ojemann, LM, Shastri RA, Wilensky AJ, Friel PN, Levy RH, McLean JR, Buchanan RA (1986) Comparative pharmacokinetics of zonisamide (CI-912) in epileptic patients on carbamazepine or phenytoin monotherapy. Ther Drug Monit 8: 293-296
88. 88. Sackellares JC, Donofrio PD, Wagner JG, Abou-Khalil B, Berent S, Aasved-Hoyt K (1985) Pilot study of zonisamide (1,2-benzisoxazole-3 methanesulfonamide) in patients with refractory partial seizures. Epilepsia 26: 206-211
89. 89. Seino M, Miyazaki H, Ito T (1991) Zonisamide. In: Pisani F, Perucca E, Avanzini G, Richens A (eds) New antiepileptic drugs. Epilepsy Res [Suppl 3], Elsevier, Amsterdam, pp 169-174
90. 90. Mimaki T (1998) Clinical pharmacology and therapeutic drug monitoring of zonisamide. Ther Drug Monit 20: 593-597
91. 91. Wilensky AJ, Friel PN, Ojemann LM, Dodrill CB, McCormick KB, Levy RH (1985) Zonisamide in epilepsy: a pilot study. Epilepsia 26: 212-220
92. 92. Mimaki T, Mino M, Sugimoto T, Murata R (1992) Antiepileptic effect and serum levels of zonisamide in epileptic patients with refractory seizures. In: Sunshine I (ed) Recent developments in therapeutic drug monitoring and clinical toxicology. Marcel Dekker, New York, pp 437-442
93. 93. Jürgens U (1987) Simultaneous determination of zonisamide and nine other anti-epileptic drugs and metabolites in serum. A comparison of microbore and conventional high-performance liquid chromatography. J Chromatogr 385: 233-240
94. 94. Kaibe K, Nishimura S, Ishii H, Sunahara N, Naruto S, Kurooka S (1990) Competitive binding enzyme immunoassay for zonisamide, a new antiepileptic drug, with selected paired-enzyme labeled antigen and antibody. Clin Chem 36: 24-27